Court Rules in Favor of FDA, Mylan in ‘Carve Out’ Case Involving Generic Precedex

Drug Industry Daily
A federal judge last week affirmed the FDA’s decision to approve generic versions of Hospira’s sedative Precedex under a pathway that allows manufacturers Mylan and Par to proceed with generics that “carve out” the brand firm’s method-of-use patent in the drug’s labeling.

To View This Article:


Subscribe To Drug Industry Daily